CA2837933A1 - Solution inhibitrice de la myostatine - Google Patents

Solution inhibitrice de la myostatine Download PDF

Info

Publication number
CA2837933A1
CA2837933A1 CA2837933A CA2837933A CA2837933A1 CA 2837933 A1 CA2837933 A1 CA 2837933A1 CA 2837933 A CA2837933 A CA 2837933A CA 2837933 A CA2837933 A CA 2837933A CA 2837933 A1 CA2837933 A1 CA 2837933A1
Authority
CA
Canada
Prior art keywords
myostatin
muscle
follistatin
chemical composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837933A
Other languages
English (en)
Inventor
Erwin Paydar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2837933A priority Critical patent/CA2837933A1/fr
Publication of CA2837933A1 publication Critical patent/CA2837933A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2837933A 2013-12-24 2013-12-24 Solution inhibitrice de la myostatine Abandoned CA2837933A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2837933A CA2837933A1 (fr) 2013-12-24 2013-12-24 Solution inhibitrice de la myostatine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2837933A CA2837933A1 (fr) 2013-12-24 2013-12-24 Solution inhibitrice de la myostatine

Publications (1)

Publication Number Publication Date
CA2837933A1 true CA2837933A1 (fr) 2015-06-24

Family

ID=53491749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837933A Abandoned CA2837933A1 (fr) 2013-12-24 2013-12-24 Solution inhibitrice de la myostatine

Country Status (1)

Country Link
CA (1) CA2837933A1 (fr)

Similar Documents

Publication Publication Date Title
AU2019200797B2 (en) Follistatin in treating duchenne muscular dystrophy
Rodino‐Klapac et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
JP2021164472A (ja) 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP1853293B1 (fr) Thymosine beta 4 pour le traitement de la sclérose en plaques
US8796199B2 (en) Uses of Cerberus and derivatives thereof
US20090233854A1 (en) Novel application of apelin
EP1799709B1 (fr) Isoforme de myostatine
CA2837933A1 (fr) Solution inhibitrice de la myostatine
Sakuma et al. Inhibitors of myostatin-and proteasome-dependent signaling for attenuating muscle wasting
US9045553B2 (en) Cerberus/Coco derivatives and uses thereof
Minderis Skeletal muscle mass and specific force: effects of genetic background and myostatin dysfunction in response to hypertrophic and atrophic stimuli in mice
EP3443980A1 (fr) Composé pour le traitement des patients avec l'obésité résistante à la leptine, le syndrome de bardet-biedl et d'autres ciliopathies
R Wagner Clinical applications of myostatin inhibitors for neuromuscular diseases
EP2135618B1 (fr) SF6 pour son utilisation dans le traitement du diabète et / ou de l'obésité, méthodes de criblage pour modulateurs et Kit

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161228